Skip to main content
Top
Published in: BMC Infectious Diseases 1/2011

Open Access 01-12-2011 | Research article

Pharmacodynamic evaluation of commonly prescribed oral antibiotics against respiratory bacterial pathogens

Authors: Carlos RV Kiffer, Antonio CC Pignatari

Published in: BMC Infectious Diseases | Issue 1/2011

Login to get access

Abstract

Background

Upper and lower respiratory tract infections (RTIs) account for a substantial portion of outpatient antibiotic utilization. However, the pharmacodynamic activity of commonly used oral antibiotic regimens has not been studied against clinically relevant pathogens. The objective of this study was to assess the probability of achieving the requisite pharmacodynamic exposure for oral antibacterial regimens commonly prescribed for RTIs in adults against bacterial isolates frequently involved in these processes (S. pneumoniae, H. influenzae, and M. catharralis).

Methods

Using a 5000-subject Monte Carlo simulation, the cumulative fractions of response (CFR), (i.e., probabilities of achieving requisite pharmacodynamic targets) for the most commonly prescribed oral antibiotic regimens, as determined by a structured survey of medical prescription patterns, were assessed against local respiratory bacterial isolates from adults in São Paulo collected during the same time period. Minimal inhibitory concentration (MIC) of 230 isolates of Streptococcus pneumoniae (103), Haemophilus influenzae (98), and Moraxella catharralis (29) from a previous local surveillance were used.

Results

The most commonly prescribed antibiotic regimens were azithromycin 500 mg QD, amoxicillin 500 mg TID, and levofloxacin 500 mg QD, accounting for 58% of the prescriptions. Varied doses of these agents, plus gatifloxacin, amoxicillin-clavulanate, moxifloxacin, and cefaclor made up the remaining regimens. Utilizing aggressive pharmacodynamic exposure targets, the only regimens to achieve greater than 90% CFR against all three pathogens were amoxicillin/amoxicillin-clavulanate 500 mg TID (> 91%), gatifloxacin 400 mg QD (100%), and moxifloxacin 400 mg QD (100%). Considering S. pneumoniae isolates alone, azithromycin 1000 mg QD also achieved greater than 90% CFR (91.3%).

Conclusions

The only regimens to achieve high CFR against all three pathogen populations in both scenarios were gatifloxacin 400 mg QD, moxifloxacin 400 mg QD, and amoxicillin-clavulanate 500 mg TID. These data suggest the need for reconsideration of empiric antibiotic regimen selection among adult patients with RTIs in the São Paulo area. Additionally, this type of study could be used to optimize prescribing patterns in specific regions in light of emerging resistance.
Literature
2.
go back to reference Lim WS, Macfarlane JT, Boswell TCJ, Harrison TG, Rose D, Leinonen M, Saikku P: Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001, 56: 296-301. 10.1136/thorax.56.4.296.CrossRefPubMedPubMedCentral Lim WS, Macfarlane JT, Boswell TCJ, Harrison TG, Rose D, Leinonen M, Saikku P: Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001, 56: 296-301. 10.1136/thorax.56.4.296.CrossRefPubMedPubMedCentral
3.
go back to reference Austrian R: Pneumococcus: the first one hundred years. Rev Infect Dis. 1981, 3: 183-9. 10.1093/clinids/3.2.183.CrossRefPubMed Austrian R: Pneumococcus: the first one hundred years. Rev Infect Dis. 1981, 3: 183-9. 10.1093/clinids/3.2.183.CrossRefPubMed
4.
go back to reference Goldblatt D: Recent developments in bacterial conjugates vaccines. J Med Microbiol. 1998, 47: 563-7. 10.1099/00222615-47-7-563.CrossRefPubMed Goldblatt D: Recent developments in bacterial conjugates vaccines. J Med Microbiol. 1998, 47: 563-7. 10.1099/00222615-47-7-563.CrossRefPubMed
5.
go back to reference Zettler EW, Scheibe RM, Dias CAG, Santafe P, Moreira JS, Santos DS, Fritscher CC: Polymerase chain reaction used to detect Streptococcus pneumoniae resistance to penicillin. J Bras Pneumol. 2004, 30 (6): 521-27.CrossRef Zettler EW, Scheibe RM, Dias CAG, Santafe P, Moreira JS, Santos DS, Fritscher CC: Polymerase chain reaction used to detect Streptococcus pneumoniae resistance to penicillin. J Bras Pneumol. 2004, 30 (6): 521-27.CrossRef
6.
go back to reference Burman LA, Norrby R, Trollfors B: Invasive pneumococcal infections: incidence, predisposing factors and prognosis. Rev Infect Dis. 1985, 7: 133-42. 10.1093/clinids/7.2.133.CrossRefPubMed Burman LA, Norrby R, Trollfors B: Invasive pneumococcal infections: incidence, predisposing factors and prognosis. Rev Infect Dis. 1985, 7: 133-42. 10.1093/clinids/7.2.133.CrossRefPubMed
7.
go back to reference Butler JC, Dowel SF, Breiman RF: Epidemiology of emerging pneumococcal drug resistance: implications for treatment and prevention. Vaccine. 1998, 16: 1693-7. 10.1016/S0264-410X(98)00132-7.CrossRefPubMed Butler JC, Dowel SF, Breiman RF: Epidemiology of emerging pneumococcal drug resistance: implications for treatment and prevention. Vaccine. 1998, 16: 1693-7. 10.1016/S0264-410X(98)00132-7.CrossRefPubMed
8.
go back to reference Murphy TF, Parameswaran GI: Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis. 2009, 49 (1): 124-31. 10.1086/599375.CrossRefPubMed Murphy TF, Parameswaran GI: Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis. 2009, 49 (1): 124-31. 10.1086/599375.CrossRefPubMed
10.
go back to reference Bradley JS, Dudley MN, Drusano GL: Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J. 2003, 11: 982-92.CrossRef Bradley JS, Dudley MN, Drusano GL: Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J. 2003, 11: 982-92.CrossRef
11.
go back to reference Barbour A, Scaglione F, Derendorf H: Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices. Int J Antimicrob Agents. 2010, 35 (5): 431-8. 10.1016/j.ijantimicag.2010.01.023.CrossRefPubMed Barbour A, Scaglione F, Derendorf H: Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices. Int J Antimicrob Agents. 2010, 35 (5): 431-8. 10.1016/j.ijantimicag.2010.01.023.CrossRefPubMed
12.
go back to reference AAP Subcommittee on Management of Sinusitis, AAP Committee on Quality Improvement: Clinical practice guideline: management of sinusitis. Pediatrics. 2001, 108 (3): 798-808.CrossRef AAP Subcommittee on Management of Sinusitis, AAP Committee on Quality Improvement: Clinical practice guideline: management of sinusitis. Pediatrics. 2001, 108 (3): 798-808.CrossRef
13.
go back to reference Sinus and Allergy Health Partnership: Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngology-Head Neck Surg. 2004, 130 (1): 1-45. Sinus and Allergy Health Partnership: Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngology-Head Neck Surg. 2004, 130 (1): 1-45.
14.
go back to reference AAP and AAFP Subcommittee on Management of Acute Otitis Media: Clinical practice guideline: diagnosis and management of acute otitis media. Pediatrics. 2004, 113 (5): 1451-65.CrossRef AAP and AAFP Subcommittee on Management of Acute Otitis Media: Clinical practice guideline: diagnosis and management of acute otitis media. Pediatrics. 2004, 113 (5): 1451-65.CrossRef
15.
go back to reference Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: twentieth informational supplement M100-S20. 2010, CLSI, Wayne, Pa Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: twentieth informational supplement M100-S20. 2010, CLSI, Wayne, Pa
16.
go back to reference Spyker DA, Rugloski RJ, Vann RI, O'Brien WM: Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration. Antimicrob Agents Chemother. 1977, 11 (1): 132-141.CrossRefPubMedPubMedCentral Spyker DA, Rugloski RJ, Vann RI, O'Brien WM: Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration. Antimicrob Agents Chemother. 1977, 11 (1): 132-141.CrossRefPubMedPubMedCentral
17.
go back to reference Liu P, Allaudeen H, Chandra R, Phillips K, Jungnik A, Breen JD, Sharma A: Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemother. 2007, 51 (1): 103-109. 10.1128/AAC.00852-06.CrossRefPubMed Liu P, Allaudeen H, Chandra R, Phillips K, Jungnik A, Breen JD, Sharma A: Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemother. 2007, 51 (1): 103-109. 10.1128/AAC.00852-06.CrossRefPubMed
18.
go back to reference Chien SC, Rogge MC, Gisclon LG, Curtin C, Wong F, Natarajan J, Williams RR, Fowler CL, Cheung WK, Chow AT: Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother. 1997, 41 (10): 2256-2260.PubMedPubMedCentral Chien SC, Rogge MC, Gisclon LG, Curtin C, Wong F, Natarajan J, Williams RR, Fowler CL, Cheung WK, Chow AT: Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother. 1997, 41 (10): 2256-2260.PubMedPubMedCentral
19.
go back to reference Stass H, Dalhoff A, Kubitza D, Schuhly U: Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother. 1998, 42 (8): 2060-2065.PubMedPubMedCentral Stass H, Dalhoff A, Kubitza D, Schuhly U: Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother. 1998, 42 (8): 2060-2065.PubMedPubMedCentral
20.
go back to reference Nakashima M, Uematsu T, Kosuge K, Kusajima H, Ooie T, Masuda Y, Ishida R, Uchida H: Single- and multiple-dose pharmacokinetics of am-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother. 1995, 39 (12): 2635-2640.CrossRefPubMedPubMedCentral Nakashima M, Uematsu T, Kosuge K, Kusajima H, Ooie T, Masuda Y, Ishida R, Uchida H: Single- and multiple-dose pharmacokinetics of am-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother. 1995, 39 (12): 2635-2640.CrossRefPubMedPubMedCentral
21.
22.
go back to reference Burgess DS, Frei CR, Lewis JS, Fiebelkorn KS, Jorgensen JH: The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitides. Clin Microbiol Infect. 2007, 13: 33-39. 10.1111/j.1469-0691.2006.01617.x.CrossRefPubMed Burgess DS, Frei CR, Lewis JS, Fiebelkorn KS, Jorgensen JH: The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitides. Clin Microbiol Infect. 2007, 13: 33-39. 10.1111/j.1469-0691.2006.01617.x.CrossRefPubMed
23.
go back to reference Alou L, Aguilar D, Sevillano D, Gimenez MJ, Gonzalez N, Echevarria O, Torrico M, Martin JE, Valdes L, Prieto J: Levofloxacin vs azithromycin pharmacodynamic activity against S. pneumoniae and H. influenzae with decreased susceptibility to amoxicillin/clavulanic acid. J Chem. 2007, 19 (6): 670-672. Alou L, Aguilar D, Sevillano D, Gimenez MJ, Gonzalez N, Echevarria O, Torrico M, Martin JE, Valdes L, Prieto J: Levofloxacin vs azithromycin pharmacodynamic activity against S. pneumoniae and H. influenzae with decreased susceptibility to amoxicillin/clavulanic acid. J Chem. 2007, 19 (6): 670-672.
24.
go back to reference Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF: Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2001, 45: 2793-2797. 10.1128/AAC.45.10.2793-2797.2001.CrossRefPubMedPubMedCentral Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF: Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2001, 45: 2793-2797. 10.1128/AAC.45.10.2793-2797.2001.CrossRefPubMedPubMedCentral
25.
go back to reference Mendes C, Kiffer CRV, Blosser-Middleton RS, Jones ME, Karlowsky JA, Barth A, Rossi F, Andrade S, Sader HS, Thornsberry C, Sahm DF: Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens--a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002. Clin Microbiol Infect. 2004, 10: 521-526. 10.1111/j.1469-0691.2004.00870.x.CrossRefPubMed Mendes C, Kiffer CRV, Blosser-Middleton RS, Jones ME, Karlowsky JA, Barth A, Rossi F, Andrade S, Sader HS, Thornsberry C, Sahm DF: Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens--a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002. Clin Microbiol Infect. 2004, 10: 521-526. 10.1111/j.1469-0691.2004.00870.x.CrossRefPubMed
26.
go back to reference Castañeda E, Agudelo CI, Regueira M, Corso A, Brandileone MC, Brandão AP, Maldonado A, Hormazabal JC, Martínez IT, Llanes R, Sánchez J, Feris JM, Echaniz-Aviles G, Carnalla-Barajas MN, Terrazas MG, Monroy IH, Chamorro G, Weiler N, Camou T, Gabarrot GG, Spadola E, Payares D, Gabastou JM, Di Fabio JL, de la Hoz F, SIREVA II Group: Laboratory-based surveillance of Streptococcus pneumoniae invasive disease in children in 10 Latin American countries: a SIREVA II project, 2000-2005. Pediatr Infect Dis J. 2009, 28 (9): 265-70. 10.1097/INF.0b013e3181a74b22.CrossRef Castañeda E, Agudelo CI, Regueira M, Corso A, Brandileone MC, Brandão AP, Maldonado A, Hormazabal JC, Martínez IT, Llanes R, Sánchez J, Feris JM, Echaniz-Aviles G, Carnalla-Barajas MN, Terrazas MG, Monroy IH, Chamorro G, Weiler N, Camou T, Gabarrot GG, Spadola E, Payares D, Gabastou JM, Di Fabio JL, de la Hoz F, SIREVA II Group: Laboratory-based surveillance of Streptococcus pneumoniae invasive disease in children in 10 Latin American countries: a SIREVA II project, 2000-2005. Pediatr Infect Dis J. 2009, 28 (9): 265-70. 10.1097/INF.0b013e3181a74b22.CrossRef
27.
go back to reference Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GC, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infect Dis. 2007, 44: S27-72. 10.1086/511159.CrossRef Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GC, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infect Dis. 2007, 44: S27-72. 10.1086/511159.CrossRef
28.
go back to reference Nicolau DP, Ambrose PG: Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. Am J Med. 2001, 111 (Suppl 9A): 13S-18S.CrossRefPubMed Nicolau DP, Ambrose PG: Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. Am J Med. 2001, 111 (Suppl 9A): 13S-18S.CrossRefPubMed
29.
go back to reference Noreddin AM, Marras TK, Sanders K, Chan CK, Hoban DJ, Zhanel GG: Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents. 2004, 24 (5): 479-84. 10.1016/j.ijantimicag.2004.06.010.CrossRefPubMed Noreddin AM, Marras TK, Sanders K, Chan CK, Hoban DJ, Zhanel GG: Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents. 2004, 24 (5): 479-84. 10.1016/j.ijantimicag.2004.06.010.CrossRefPubMed
30.
go back to reference Noreddin AM, Hoban DJ, Zhanel GG: Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Int J Antimicrob Agents. 2005, 26 (2): 120-5. 10.1016/j.ijantimicag.2005.04.012.CrossRefPubMed Noreddin AM, Hoban DJ, Zhanel GG: Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Int J Antimicrob Agents. 2005, 26 (2): 120-5. 10.1016/j.ijantimicag.2005.04.012.CrossRefPubMed
31.
go back to reference Jones RN, Rubino CM, Bhavnani SM, Ambrose PG: Antimicrobial resistance rate epidemiology study team program. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother. 2003, 47 (1): 292-6. 10.1128/AAC.47.1.292-296.2003.CrossRefPubMedPubMedCentral Jones RN, Rubino CM, Bhavnani SM, Ambrose PG: Antimicrobial resistance rate epidemiology study team program. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother. 2003, 47 (1): 292-6. 10.1128/AAC.47.1.292-296.2003.CrossRefPubMedPubMedCentral
32.
go back to reference Pichichero ME, Doern GV, Kuti JL, Nicolau DP: Probability of achieving requisite pharmacodynamic exposure for oral β-lactam regimens against Haemophilus influenzae in Children. Pediatr Drugs. 2008, 10 (6): 1-7.CrossRef Pichichero ME, Doern GV, Kuti JL, Nicolau DP: Probability of achieving requisite pharmacodynamic exposure for oral β-lactam regimens against Haemophilus influenzae in Children. Pediatr Drugs. 2008, 10 (6): 1-7.CrossRef
Metadata
Title
Pharmacodynamic evaluation of commonly prescribed oral antibiotics against respiratory bacterial pathogens
Authors
Carlos RV Kiffer
Antonio CC Pignatari
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2011
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-11-286

Other articles of this Issue 1/2011

BMC Infectious Diseases 1/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.